Children with cancer can’t wait any longer
06 Dec 2016 – 10:09 | No Comment

The EU Paediatric Medicines Regulation has benefited a series of childhood diseases, yet only two innovative anti-cancer drugs have been authorised so far. Francoise Grossetete MEP analyses the impact of the legislation and points out …

Read the full story »
International

EU Health

Transport

Circular Economy

Climate Change

Home » Archive by Tags

Articles tagged with: prostate cancer

European Commission’s action on health priorities
31 Mar 2016 – 13:14
European Commission’s action on health priorities

In an exclusive interview with Government Gazette, Vytenis Andriukaitis, European Commissioner for Health and Food Safety, discusses the EU action on cancer, diabetes and healthcare technology
The incidence of prostate cancer and diabetes has significantly increased …

Towards a paradigm shift in diagnosis and management
31 Mar 2016 – 10:00
Towards a paradigm shift in diagnosis and management

Over the past years, there has been a fundamental change in the way prostate cancer has been diagnosed and treated, with patients having a greater variety of options to choose from. Prof Ronald Van Velthoven, …

Reducing mortality rates tops MAC’s latest agenda
31 Mar 2016 – 10:00
Reducing mortality rates tops MAC’s latest agenda

The MEPs Against Cancer (MAC) group strives to reduce cancer incidence by promoting prevention, reducing mortality through equitable access to high-quality care and ensuring good quality of life for cancer patients. MEP Nessa Childers, Vice …

The five faces of prostate cancer
31 Mar 2016 – 10:00
The five faces of prostate cancer

Prostate cancer can no longer be treated as one disease. Dr. Alastair Lamb, Clinical Lecturer in Urology, Cambridge Biomedical Campus, UK, outlines some recent work identifying genetic subtypes of prostate cancer and how this could …

Active surveillance – a great alternative to curative therapies
30 Mar 2016 – 17:29
Active surveillance – a great alternative to curative therapies

The ‘active surveillance’ protocol has become an alternative to curative therapy for prostate cancer that is unlikely to be biologically or clinically significant. However, Dr Riccardo Valdagni, Director, Radiation Oncology, European School of Oncology says …

Innovative therapies must be made accessible to all
30 Mar 2016 – 17:27
Innovative therapies must be made accessible to all

Access pathways must foster innovation to address unmet needs, align evidence requirements as treatment options move earlier in the disease course, and remove barriers to access for patients. Jane Griffiths, Group Chairman, Janssen Europe, Middle …

Symptoms, treatment, follow-up & everything about PCa
30 Mar 2016 – 17:16
Symptoms, treatment, follow-up & everything about PCa

Dr. Laurent Fossion, M.D., Urologist, FeBU, gives the whole picture on care, prevention and treatment of prostate cancer in Europe
Exact causes for prostate cancer are still unknown, but dietary habits (Western feeding pattern) and genetic …

From therapeutic nihilism to diversity in treatment options – what can be added?
30 Mar 2016 – 17:11
From therapeutic nihilism to diversity in treatment options – what can be added?

Despite extensive use of radical treatments, such as surgery and radiotherapy, and constant technical innovations, mortality rates remain high. Prof Bertand Tombal, Consultant Urologist, Brussels Saint-Luc University Hospital lists out whats missing in the battle …

Calling for a compulsory screening mechanism in UK
30 Mar 2016 – 17:06
Calling for a compulsory screening mechanism in UK

All cancers are required to be diagnosed sufficiently early if treatment should to be successful and prostate cancer appears to be the most difficult as patients often show no early symptoms. Gary Steele, M.B.E, Chairman, …

Improving European healthcare with evidence-based information
30 Mar 2016 – 16:59
Improving European healthcare with evidence-based information

For almost 40 years, the European Association of Urology has addressed the most pressing concerns of urological diseases. Prof. Dr. Nicolas Mottet and Prof. Dr. Hein Van Poppel — on behalf of the EAU — …